Evidence map›Paper›PMID 39432022›Full record

SynthesisLangenbeck's archives of surgery2024

The impact of adrenocortical carcinoma hormone secreting status as a predictor of poor survival: a systematic review and meta-analysis.

Constantinos Nastos, Dimitrios Papaconstantinou, Anna Paspala, Nikolaos Pararas, Andromachi Vryonidou, Anastasia Pikouli, Eirini Chronopoulou, Anna Lechou, Melpomeni Peppa, Emmanouil Pikoulis

Abstract readSystematic ReviewMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Langenbeck's archives of surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Hormonal functional status and prognostic stratification in adrenocortical carcinoma: a single-center retrospective cohort study.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Constantinos NastosThird Department of Surgery, National and Kapodistrian University of Athens, Attikon University Hospital, 1 Rimini Str, Athens, 12462, Greece.
Dimitrios PapaconstantinouThird Department of Surgery, National and Kapodistrian University of Athens, Attikon University Hospital, 1 Rimini Str, Athens, 12462, Greece. Dimpapa7@hotmail.com.
Anna PaspalaThird Department of Surgery, National and Kapodistrian University of Athens, Attikon University Hospital, 1 Rimini Str, Athens, 12462, Greece.
Nikolaos PararasThird Department of Surgery, National and Kapodistrian University of Athens, Attikon University Hospital, 1 Rimini Str, Athens, 12462, Greece.
Andromachi VryonidouDepartment of Endocrinology and Diabetes Center, Hellenic Red Cross Hospital, Athens, Greece.
Anastasia PikouliThird Department of Surgery, National and Kapodistrian University of Athens, Attikon University Hospital, 1 Rimini Str, Athens, 12462, Greece.
Eirini ChronopoulouDepartment of Pediatric Surgery, Agia Sophia Children's Hospital, Athens, Greece.
Anna LechouThird Department of Surgery, National and Kapodistrian University of Athens, Attikon University Hospital, 1 Rimini Str, Athens, 12462, Greece.
Melpomeni PeppaEndocrine Unit, Second Department of Internal Medicine Propaedeutic, Research Institute and Diabetes Center, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Emmanouil PikoulisThird Department of Surgery, National and Kapodistrian University of Athens, Attikon University Hospital, 1 Rimini Str, Athens, 12462, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAdrenocortical carcinoma (ACC) poses a significant challenge in healthcare due to its aggressive nature and rarity. Prior reports suggest a poorer prognosis associated with hormone-secreting neoplasms. This study aims to assess the impact of ACC hormonal status on patients' oncologic survival.

methodsA comprehensive literature search of the Medline, Embase, Web of Science, CINAHL, CENTRAL and clinicaltrials.gov databases was undertaken. Utilized data involved Hazard Ratios derived from multivariable analysis in order to minimize exposure to confounding bias. Included studies were subsequently meta-analyzed using a Random effects model.

resultsTwelve studies incorporating 4483 patients were included in the quantitative analysis. Hormonally active ACCs comprised 48% of the entire pooled patient cohort and were found to be associated with significantly worse Overall Survival (HR 1.57, 95% Confidence Interval 1.39-1.78, p < 0.001). Disease-Free Survival was comparably impacted (HR 1.32, 95% CI 1.11-1.57, p < 0.001). Furthermore, cortisol secreting ACCs specifically, were also found to be associated with a 48% increase in the hazard of death or disease recurrence. Interstudy statistical heterogeneity was minimal among evaluated outcomes.

conclusionsHormone-producing ACCs exhibit a poorer prognosis compared to non-secreting counterparts, with a 57% increased risk of death and a 32% increased risk of recurrence. These findings support the hypothesis that hormone production signifies an adverse tumor-specific feature, particularly when leading to hypercortisolemia, indicating an aggressive disease phenotype.

Indexed as

Adrenal Cortex NeoplasmsAdrenocortical CarcinomaHumansHydrocortisonePrognosisSurvival RateHydrocortisoneAdrenocortical carcinomaCortisolHormoneMeta-analysisSecreting

Identifiers

PMID39432022

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.